Background: The use of psychological therapies for patients with psoriasis has been proposed based on observations that the severity of their disease may correlate with emotional stress. The aim of this pilot study was to evaluate the effect of hypnosis as a treatment modality for patients with psoriasis. Methods: We performed a 3-month randomized, single-blind, controlled trial of the use of hypnosis in adults with stable, chronic, plaque-type psoriasis. Highly or moderately hypnotizable subjects were randomized to receive either hypnosis with active suggestions of improvement (5 patients) or neutral hypnosis with no mention of their disease process (6 patients). After this period, the study was unblinded, and all the patients were treated for an additional 3 months with hypnosis with active suggestions of improvement. Results: Highly hypnotizable subjects showed significantly greater improvement than did moderately hypnotizable subjects, independent of treatment group assignment (active suggestion or neutral hypnosis). Conclusion: Although this study included a very limited number of patients, the results suggest that hypnosis may be a useful therapeutic modality for highly hypnotizable subjects with psoriasis, and merits further testing in a larger patient population.

Keywords:
Dermatology, Psoriasis, Psychodermatology, Psychosomatic, Hypnosis, Psychotherapy
1.
Koblenzer CS: Psychologic aspects of skin disease; in Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF (eds): Dermatology in General Medicine, ed 4. New York, McGraw-Hill, 1993, pp 14–26.
2.
Farber EM, Nall L: Psoriasis: A stress-related disease. Cutis 1993;51:3226.
3.
Winchell SA,Watts RA: Relaxation therapies in the treatment of psoriasis and a possible pathophysiologic mechanism. J Am Acad Dermatol 1988;18:101–104.
4.
Seville RH: Psoriasis and stress. Br J Dermatol 1977;97:297–302.
5.
Gaston L, Lassonde M, Bernier-Buzzanga J, et al: Psoriasis and stress: A prospective study. J Am Acad Dermatol 1987;17:82–86.
6.
Medansky RS, Handler RM: Dermatopsychosomatics: Classification, physiology, and therapeutic approaches. J Am Acad Dermatol 1981; 5:125–136.
7.
Frankel FH , Misch RC: Hypnosis in a case of long-standing psoriasis in a person with character problems. Int J Clin Exp Hypnosis 1973; 21:121–130.
8.
Hughe HH, England R, Goldsmith DA: Biofeedback and psychotherapeutic treatment of psoriasis: A brief report. Psychol Rep 1981;48:99–102.
9.
Seville RH: Stress and psoriasis: The importance of insight and empathy in prognosis. J Am Acad Dermatol 1989;20:97–100.
10.
Diehl F, Heinichen W: Psychische Beeinflussung allergischer Reaktionen. Münch Med Wochenschr 1931;78:1008–1009.
11.
Clarkson AK: The nervous factor in juvenile asthma. Br Med J 1937;ii:845–850.
12.
Black S: Inhibition of immediate-type hypersensitivity response by direct suggestion under hypnosis. Br Med J 1963;6:925–929.
13.
Black S: Shift in dose-response curve of Prausnitz-Kustner reaction by direct suggestion under hypnosis. Br Med J 1963;6:990–992.
14.
Black S, Humphrey JH, Niven JSF: Inhibition of Mantoux reaction by direct suggestion under hypnosis. Br Med J 1963;6:1649–1652.
15.
Zachariae R, Bjerring P, Arendt-Nielsen L: Modulation of type I immediate and type IV delayed immunoreactivity using direct suggestion and guided imagery during hypnosis. Allergy 1989;44:537–542.
16.
Zachariae R, Hansen JB, Andersen M, Jinquan T, Petersen KS, Simonsen C, Zachariae C, Thestrup-Pedersen K: Changes in cellular immune function after immune specific guided imagery and relaxation in high and low hypnotizable healthy subjects. Psychother Psychosom 1994;61:74–92.
17.
Zachariae R, Bjerring P: The effect of hypnotically induced analgesia on flare reaction of cutaneous histamine prick test. Arch Dermatol Res 1990;282:539–543.
18.
Zachariae R, Bjerring P: Increase and decrease of cutaneous reactions obtained by hypnotic suggestions during sensitization. Allergy 1993;48:6–16.
19.
Olness K, Culvert T, Uden D: Self-regulation of salivary immunoglobulin A by children. Pediatrics 1989;83:66–71.
20.
Hall HR, Minnes L, Tosi M, Olness K: Voluntary modulation of neutrophil adhesiveness using a cyberphysiologic strategy. Int J Neurosci 1992;63:287–297.
21.
Locke SE, Ransil BJ, Zachariae R, Molay F, Tollins K, Corino NA, Danforth D: Effect of hypnotic suggestion on the delayed-type hypersensitivity response. JAMA 1994;47–52.
22.
Laidlaw TM, Richardson DH, Booth RJ, Large RG: Immediate-type hypersensitivity reactions and hypnosis: Problems in methodology. J Psychosom Res 1994;38:569–578.
23.
Covino NA, Frankel FH: Hypnosis and relaxation in the medically ill. Psychother Psychosom 1993;60:75–90.
24.
Mirvish I: Hypnotherapy for the child with chronic eczema: A case report. S Afr Med J 1978;54:410–411.
25.
Stewart AC, Thomas SE: Hypnotherapy as a treatment for atopic dermatitis in adults and children. Br J Dermatol 1995;132:778–783.
26.
Shertzer CL, Lookingbill DP: Effects of relaxation therapy and hypnotizability in chronic urticaria. Arch Dermatol 1987;123:913–916.
27.
Surman OS, Gottlieb SK, Hackett TP: Hypnotic treatment of a child with warts. Am J Clin Hypn 1972;15:12–14.
28.
Surman OS, Gottlieb SK, Hackett TP, Silverberg EL: Hypnosis in the treatment of warts. Arch Gen Psychiatry 1973;28:439–441.
29.
Chrousos GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351–1362.
30.
Ansel JC, Kaynard AH, Armstrong CA et al: Skin-nervous system interactions. Prog Dermatol 1995;29:1–12.
31.
Tausk F, Christian E, Johansson O, Milgram S: Neurobiology of the skin; in Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF (eds). Dermatology in General Medicine, ed 4. New York, McGraw-Hill, 1993, pp 396–403.
32.
Pincelli C, Fantini F, Magnoni C, Gianetti A: Psoriasis and the nervous system. Acta Derm Venereol (Stockh) 1994(suppl 186):60–61.
33.
Farber EM, Lanigan SW, Boer J: The role of cutaneous sensory nerves in the maintenance of psoriasis. Int J Dermatol 1990;29:418–420.
34.
Naukkarinen A, Nickoloff BJ, Farber EM: Quantification of cutaneous sensory nerves and their substance P content in psoriasis. J Invest Dermatol 1989;92:126–129.
35.
Eedy DJ, Johnston CF, Shaw C, Buchanan KD: Neuropeptides in psoriasis: An immunocytochemical and radioimmunoassay study. J Invest Dermatol 1991;96:434–438.
36.
Haegerstrand A, Jonzon B, Dalsgaard CJ, Nilsson J: Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes. Proc Natl Acad Sci USA 1989;86:5993–5996.
37.
Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH Jr: Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol 1986;15:504–507.
38.
Harvima IT, Viinamaki H, Naukkarinen A, Neittaanmaki H, Harvima RJ, Horsmanheimo M: Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis. Psychother Psychosom 1993;60:168–176.
39.
Weitzenhoffer AM, Hilgard ER: Stanford Hypnotic Susceptibility Scale, Form C. Palo Alto, Consulting Psychologist Press, 1962.
40.
Fredriksson T, Petterson U: Severe psoriasis: Oral therapy with a new retinoid. Dermatologica 1978;157:238–244.
41.
Zachariae R, Oster H, Bjerring P, K Kragbelle: Effects of psychologic intervention on psoriasis: A preliminary report. J Am Acad Dermatol 1996;34:1008–1015.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.